Skip to main content
Home
  • About
    • Board of Directors
    • Our Staff
    • Careers
      • Policies
      • Annual Reports
        • 2018 Annual Report
        • 2017 Annual Report
    • Programs
      • COVID-19 Hub
      • IMEDS
        • IMEDS Network Partners
        • IMEDS Research Portfolio
        • IMEDS Steering Committee
      • EA Navigator
      • BD4P
      • FDA Patient Listening Sessions
    • News and Events
      • News
      • Events
      • Annual Public Meeting
        • 2019 Annual Public Meeting
        • 2020 Annual Public Meeting
      • Awards
    • Donate
    • COVID-19
    • facebook
    • twitter
    • linkedin
    • youtube
    Home
    • About
      • Board of Directors
      • Our Staff
      • Careers
      • Policies
      • Annual Reports
    • Programs
      • COVID-19 Hub
      • IMEDS
      • EA Navigator
      • BD4P
      • FDA Patient Listening Sessions
    • News and Events
      • News
      • Events
      • Annual Public Meeting
      • Awards
    • Donate
    • COVID-19

    News

    Breadcrumb

    1. Home
    2. News and Events
    3. FDA to facilitate access to unapproved drugs
    • facebook
    • twitter
    • email
    • print

    FDA to facilitate access to unapproved drugs

    Biocentury coverage on the FDA’s expanded access program and collaboration with the Reagan-Udall Foundation is available here: https://www.biocentury.com/biocentury/regulation/2018-12-14/how-fda-plans-help-patients-get-expanded-access-unapproved-drugs

    Support the Reagan-Udall Foundation for the FDA

    Donate
    (202) 849 - 2075
    1900 L Street NW, Suite 835
    Washington, DC 20036
    admin@reaganudall.org
    • facebook
    • twitter
    • linkedin
    • youtube

    © Reagan-Udall Foundation for the FDA
    © Reagan-Udall Foundation for the FDA